"Navigating the Modern News Zoo so you don't have to."
Wednesday, April 30, 2025
A liquid biopsy-based assay could detect recurrence prior to imaging in patients with resectable colorectal cancer
An ultrasensitive circulating tumor DNA (ctDNA)-based liquid biopsy assay detected signs of recurrence prior to imaging and provided prognostic value within one month after surgery in patients with colorectal cancer (CRC), according to interim results from the VICTORI study presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, held April 25–30.
Psycho Runs Over Cop during DUI Traffic Stop
- Best No-Appraisal Home Equity Loans of May 2025
- RFK Jr.’s bloodbath at HHS: Blowback grows as losses become clearer - Beth Mole
- Tom Homan Fires Warning Shot to Judges, Officials Knowingly Harboring Illegals: ‘You Will Be Prosecuted’ - Diana Zapata
- The Secret Reason Star Trek: The Original Series Is So Colorful - Chris Snellgrove
- When Social Security Recipients Will Get Their Checks in May
- Adjuvant PD-1 blockade for mismatch repair-deficient solid cancers directed by ctDNA status delivers clinical benefit
Finally, a Slim and Solid Samsung Midrange Phone! ft. Galaxy M56 5G
- Inside ‘Confesiones Chin Chin’: Exploring Identity and Chaos Through Unstructured Storytelling - Aayush Sharma
- Broader antibiotic use could change the course of cholera outbreaks
- 14 Best Blue Collar Jobs For Women To Make Money - Mahnoor
- How To Manage Dry Eyes With Contact Lenses - Suchandrima Bhowmik
- Israel flattens Rafah ruins; Gazans fear plan to herd them there - MeighTimbol
- US Congress passes 'Take It Down' revenge porn bill that also covers AI deepfakes - Mariella Moon
